
Bristol Myers Squibb Announces the Committee for Medicinal Products for Human Use (CHMP) has Recommended the Approval of Sotyktu (Deucravacitinib) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis
This announcement follows the September 2022 approval from the U.S. Food and Drug Administration (FDA) and the Japan’s Ministry of